Find Clinical Trial

Efficacy and safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in adult patients with arterial hypertension and dyslipidemia, 8 weeks, phase 3, randomized, double-blind, active-control, multinational, multi-center, parallel study


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationDyslipidemia, Hypertension
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

ATORVASTATIN, PERINDOPRIL,
S005167

Active Substance CodeS005167
Protocol CodeCL3-05167-005
NCT CodeNCT04591808


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility